PA
GPCR icon

Parallel Advisors’s Structure Therapeutics GPCR Stock Holding History

Parallel Advisors’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$395K Hold
7,352
– – 0.01% 907
2026
Q1 		$354K Hold
7,352
– – 0.01% 877
2025
Q4 		$511K Sell
7,352
-912
-11% -$37.2K 0.01% 674
2025
Q3 		$231K Hold
8,264
– – ﹤0.01% 987
2025
Q2 		$171K Buy
+8,264
New +$182K ﹤0.01% 1085

Other funds holding GPCR

Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
SAM
SEB Asset Management Stockholm $26.6B AUM
Universal-Beteiligungs- und Servicegesellschaft
Universal-Beteiligungs- und Servicegesellschaft Frankfurt Am Main, Germany $65.4B AUM 39.83% 1-Year Est. Return
PCM
Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
AP
Antipodes Partners Royal Exchange, Australia $5.46B AUM 26.64% 1-Year Est. Return

Parallel Advisors's GPCR Position: Q2 2026 in Review

Parallel Advisors held its Structure Therapeutics (GPCR) position steady in Q2 2026 at 7,352 shares worth $395K. The position accounts for 0.01% of the portfolio, ranked #907.

Parallel Advisors first reported a position in GPCR in Q2 2025 and has held it in 5 quarters since. The position peaked at $511K in Q4 2025. 58 funds tracked by Wall St. Rank hold GPCR as of Q2 2026.

  • Parallel Advisors held 7,352 shares of Structure Therapeutics worth $395K as of Q2 2026.
  • Parallel Advisors left its Structure Therapeutics share count unchanged in Q2 2026.
  • Structure Therapeutics made up 0.01% of Parallel Advisors's portfolio in Q2 2026, its #907 holding.
  • Parallel Advisors first reported a position in Structure Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Parallel Advisors's Structure Therapeutics position peaked at $511K in Q4 2025.
  • 58 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2026.

Based on Parallel Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.